Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 41

1.

The Current State of Pharmacological Treatments for Cannabis Use Disorder and Withdrawal.

Brezing CA, Levin FR.

Neuropsychopharmacology. 2018 Jan;43(1):173-194. doi: 10.1038/npp.2017.212. Epub 2017 Sep 6. Review.

PMID:
28875989
2.

Smoked marijuana attenuates performance and mood disruptions during simulated night shift work.

Keith DR, Gunderson EW, Haney M, Foltin RW, Hart CL.

Drug Alcohol Depend. 2017 Sep 1;178:534-543. doi: 10.1016/j.drugalcdep.2017.04.036. Epub 2017 Jun 28.

PMID:
28728115
3.

Evidence-based Treatment Options in Cannabis Dependency.

Walther L, Gantner A, Heinz A, Majić T.

Dtsch Arztebl Int. 2016 Sep 30;113(39):653-659. doi: 10.3238/arztebl.2016.0653. Review.

4.

Progress toward pharmacotherapies for cannabis-use disorder: an evidence-based review.

Copeland J, Pokorski I.

Subst Abuse Rehabil. 2016 May 3;7:41-53. doi: 10.2147/SAR.S89857. eCollection 2016. Review.

5.

Sleep abnormalities associated with alcohol, cannabis, cocaine, and opiate use: a comprehensive review.

Angarita GA, Emadi N, Hodges S, Morgan PT.

Addict Sci Clin Pract. 2016 Apr 26;11(1):9. doi: 10.1186/s13722-016-0056-7. Review.

6.

Treatment of Cannabis Use Disorder: Current Science and Future Outlook.

Sherman BJ, McRae-Clark AL.

Pharmacotherapy. 2016 May;36(5):511-35. doi: 10.1002/phar.1747. Review.

7.
8.

Outcomes from a computer-assisted intervention simultaneously targeting cannabis and tobacco use.

Lee DC, Budney AJ, Brunette MF, Hughes JR, Etter JF, Stanger C.

Drug Alcohol Depend. 2015 Oct 1;155:134-40. doi: 10.1016/j.drugalcdep.2015.08.001. Epub 2015 Aug 10.

9.

Cannabis and psychopathology: The meandering journey of the last decade.

Ghosh A, Basu D.

Indian J Psychiatry. 2015 Apr-Jun;57(2):140-9. doi: 10.4103/0019-5545.158134. Review.

10.

Pharmacotherapies for cannabis dependence.

Marshall K, Gowing L, Ali R, Le Foll B.

Cochrane Database Syst Rev. 2014;(12):CD008940. doi: 10.1002/14651858.CD008940.pub2. Epub 2014 Dec 17. Review.

11.

Do withdrawal-like symptoms mediate increased marijuana smoking in individuals treated with venlafaxine-XR?

Kelly MA, Pavlicova M, Glass A, Mariani JJ, Bisaga A, Sullivan MA, Nunes EV, Levin FR.

Drug Alcohol Depend. 2014 Nov 1;144:42-6. doi: 10.1016/j.drugalcdep.2014.06.040. Epub 2014 Jul 11.

12.

MDMA: a social drug in a social context.

Kirkpatrick MG, de Wit H.

Psychopharmacology (Berl). 2015 Mar;232(6):1155-63. doi: 10.1007/s00213-014-3752-6. Epub 2014 Oct 5.

13.

Treatment models for targeting tobacco use during treatment for cannabis use disorder: case series.

Lee DC, Budney AJ, Brunette MF, Hughes JR, Etter JF, Stanger C.

Addict Behav. 2014 Aug;39(8):1224-30. doi: 10.1016/j.addbeh.2014.04.010. Epub 2014 Apr 13.

14.

Neurocognition in college-aged daily marijuana users.

Becker MP, Collins PF, Luciana M.

J Clin Exp Neuropsychol. 2014;36(4):379-98. doi: 10.1080/13803395.2014.893996. Epub 2014 Mar 12.

15.

Pericyazine in the treatment of cannabis dependence in general practice: a naturalistic pilot trial.

Morley KC, Haber PS, Morgan ML, Samara F.

Subst Abuse Rehabil. 2012 May 28;3:43-7. doi: 10.2147/SAR.S30052. eCollection 2012.

16.

Pharmacotherapeutics for substance-use disorders: a focus on dopaminergic medications.

Verrico CD, Haile CN, Newton TF, Kosten TR, De La Garza R 2nd.

Expert Opin Investig Drugs. 2013 Dec;22(12):1549-68. doi: 10.1517/13543784.2013.836488. Epub 2013 Sep 14. Review. Erratum in: Expert Opin Investig Drugs. 2014 Jun;23(6):885. De La Garza, Richard [corrected to De La Garza, Richard 2nd].

17.

Development of an integrative cessation program for co-smokers of cigarettes and cannabis: demand analysis, program description, and acceptability.

Becker J, Hungerbuehler I, Berg O, Szamrovicz M, Haubensack A, Kormann A, Schaub MP.

Subst Abuse Treat Prev Policy. 2013 Sep 12;8:33. doi: 10.1186/1747-597X-8-33.

18.

In the company of others: social factors alter acute alcohol effects.

Kirkpatrick MG, de Wit H.

Psychopharmacology (Berl). 2013 Nov;230(2):215-26. doi: 10.1007/s00213-013-3147-0. Epub 2013 May 28.

19.

Marijuana dependence: not just smoke and mirrors.

Ramesh D, Schlosburg JE, Wiebelhaus JM, Lichtman AH.

ILAR J. 2011;52(3):295-308. doi: 10.1093/ilar.52.3.295. Review.

20.

A randomized double-blind, placebo-controlled trial of venlafaxine-extended release for co-occurring cannabis dependence and depressive disorders.

Levin FR, Mariani J, Brooks DJ, Pavlicova M, Nunes EV, Agosti V, Bisaga A, Sullivan MA, Carpenter KM.

Addiction. 2013 Jun;108(6):1084-94. doi: 10.1111/add.12108. Epub 2013 Mar 21.

Supplemental Content

Support Center